SLE - Systemic Lupus Erythematosus
13
6
6
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 13 trials
0%
0 trials in Phase 3/4
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (13)
A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis
A Study to Evaluate the Safety,Tolerability,Pharmacokinetics and Pharmacodynamics of Cenerimod in Adult Chinese Participants With Moderate-to-severe Systemic Lupus Erythematosus (SLE)
A Study of CC312 for Relapsed/Refractory Autoimmune Diseases
IASO-782 in Systemic Lupus Erythematosus
CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
Allogeneic UCB-derived CAR-T for SLE
CD19/BCMA CAR-T for SLE
MB-CART19.1 in Refractory SLE
Safety and Efficacy Study of CC312 for Moderate to Severe SLE
Does Belimumab Modify the Natural History of SLE? A Propensity Score-matched, Real-world Study
Associating Gastric Infection With Autoimmune Flare Severity in an Egyptians
OMERACT SLE Delphi
The Relation of Albumin/Globulin Ratio and Platelet/Albumin Ratio to Lupus Nephritis